CLABF - Core One Labs, Inc.

From OTC Wiki
Core One Labs Inc. is a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the "technology") which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

Related ticker symbols: CSX: COOL

Jump to: Wiki | News | Links | FAQs | Opinions

Edit Wiki page
Become Wiki Editor
Learn to edit

Company Profile[edit]

Incorporated in 2010, Core One Labs Inc. (OTC: CLABF, CSX: COOL) is a Canada-based biotechnology and life sciences firm headquartered in Vancouver. The company focuses on providing psychedelic-assisted psychotherapy, API-grade psilocybin manufacturing, and advancing psychedelic medicines to the drug market via novel delivery techniques. The company is committed to using its proprietary technologies in producing natural-based medicines to cure mental health illnesses, neurological disorders, and addiction. Its CannaStrips technology manufactures infused strips that facilitate the bioavailability of cannabis constituents. The company and its subsidiaries offer additional services, including micro-cultivation, consulting, financing, and provision of natural health products.[1] As of November 28, 2022, Core One operated 13 fully-owned subsidiaries, including Rejuva Alternative Medicine Research Centre Inc., a walk-in medical clinic in Vancouver, and Vocan Biotechnologies Inc., a genetic engineering and biosynthesis research firm. Its clinics operate a combined database of approximately 27,000 patients. The firm was originally known as Lifestyle Delivery Systems Inc. before changing its name in September 2019 to Core One Labs Inc. It is a publicly-traded company with shares listed on the Canadian Securities Exchange under the COOL symbol, on the Borse Frankfurt Exchange under the LD6, WKN: A14XHT symbol, and on OTCQX under the CLABF ticker symbol.[2]

Corporate Operations[edit]

Core One employs a multi-facet business strategy incorporating diversified and complementary business categories and units to establish its footprint in the ever-growing psychedelics market. It pursues the development and commercialization of swift-onset treatment solutions that improve the quality of life while maximizing returns for investors. The firm focuses on researching and developing novel biologically synthesized cGMP API-grade psychedelic compounds and generating psychedelic-assisted modes for treating mental health and neurological complications.[3]

Through research and proprietary delivery methods used by the CannaStrip technology, the company is committed to increasing the efficacy and bioavailability of its existing drug portfolio, including psilocybin, distributed via clinics. The bioavailability of cannabis constituents in Core One’s proprietary technology increases the absorption efficiency of the ingredients, which is vital for patients seeking alternative health treatments. Core One closed the double acquisition of Rejuva Alternative Medicine Research Centre Inc. and 25% of the non-voting share capital of Shahcor Health Services Inc. in July 2020. Rejuva and Shahcor are privately held and maintain a client base of more than 200,000.

The company later in December 2020, acquired Vocan Biotechnologies Inc., a certified Canada-based genetic engineering and biosynthesis research company developing an economical production approach to biosynthesize GMP API-grade psilocybin. Vocan’s team of Scientists specializing in biosynthetic fermentation and protein expression discovered a patentable method for producing psilocybin, an active ingredient in psychotropic mushrooms. On December 31, 2020, the company successfully disposed of a significant number of its non-core assets to focus more on the psychedelic space and the development of its CannaStrip technology. The world antidepressant drug market was valued at $13.7 billion in 2016 and was projected to hit $15.9 billion by 2023 with a CAGR of 2.1%.[4]

Corporate Business History[edit]

Core One changed its name from Lifestyle Delivery Systems Inc. to accurately reflect its functional specialization and capture a perfect scope of its products and services. It was initially a technology firm that used its technology to operate a state-of-the-art production and packaging plant in Southern California. Through Core Isogenics Inc. and CSPA Group Inc., its wholly owned subsidiaries, Core One managed a licensed vertically integrated cannabis cultivation, manufacturing, and distribution project in Adelanto, California. It operates in two locations; British Columbia, Canada, and California, USA.[4]

Critical Company Updates[edit]

On January 24, 2023, Core One reported Akome Biotech Ltd., its wholly-owned subsidiary, had completed the Phase 1 study of parameters as per its September 2022 press release and consequently entered into a binding contract with Fundació Bosh I Gimpera, representing the University of Barcelona, to initiate Phase 2 studies. The studies aim to investigate the therapeutic potential of the company’s bio-compounds, independently and jointly with various psychedelic components on the central nervous system. Results of the studies are vital to Akome's pre-clinical development of generational psychedelic drug options for treating a range of neurological disorders, including Ischemic Stroke, Parkinson's Disease, and depression.[5]

On January 13, 2023, the company announced that it had successfully acquired GMP Drug Inc., a privately-owned firm that operates a certified GMP facility in Ontario. GMP Drug’s pharmaceutical drugs production facility holds a CDSA Dealer's License, a US FDA registration, and meets all the Food and Drug Regulations in Canada. The laboratory can produce GMP Active Pharmaceutical Ingredient (API) grade compounds comprising those of scheduled psychedelics. The acquisition will boost Core One’s production and allow it to become a full-cycle psychedelic distributor for the Canadian and global markets. GMP Drug’s facility will provide Core One’s subsidiaries with an equipped facility needed to expand research and production.[6]

Core One released its MDA for the nine months that ended September 30, 2022, on November 28, 2022. Highlights of the company’s third-quarter financial results include:

  • Recorded $1,181,977in net losses compared to $5,532,986 in the same quarter of 2021
  • Total expenditures decreased to $1,169,873 from $1,246,965 in the third quarter of 2021
  • Closed the quarter with a cash balance of $145,809 compared to $763,345 on December 31, 2021.[7]

Leadership Team[edit]

Joel Shacker, CEO

  • Has seven years of extensive experience working in the cannabis and finance sectors
  • Was the CEO of Thoughtful Brands Inc, an e-commerce cannabis company, before joining Core One
  • Has worked across different regions, including Europe, Central America, North America, and South America
  • His expertise and business acumen have seen him acquire and integrate more than 20 different properties in various industries, summing to over $150,000,000 in acquisitions in his career.

Dr. Santiago Ferro, Chief Medical Officer

  • An internationally renowned physician with more than 20 years of experience in the biological, pharmaceuticals, and biotech industries
  • He has held numerous senior research and development positions where he was responsible for clinical development programs, design, implementation, and analysis of clinical trial data.
  • He has a track record of relationship building, project management, and clinical plan designing to produce trendy market products.
  • He graduated from Javeriana University Medical School, where he specialized in Internal Medicine.
  • He later acquired his sub-specialty training in Infectious Diseases at the University of Toronto.

Jan Burian, Chief Technical Officer at Vocan Biotechnologies

  • A successful molecular biologist and biochemist with exquisite knowledge in operations, research and development, and fermentative API-production scale-up
  • He was previously a site director at Pfizer.[8]

References[edit]

Create News


Sat, 00:25 January 14, 2023 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Tue, 19:02 December 13, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Fri, 22:32 November 25, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Sat, 00:56 November 19, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Thu, 17:49 November 10, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Wed, 20:18 November 9, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Fri, 23:55 October 21, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Fri, 23:59 October 14, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Sat, 00:00 October 8, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Fri, 23:55 September 30, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Thu, 23:36 September 29, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Sat, 00:29 September 24, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Fri, 23:55 September 16, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Fri, 23:55 September 2, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Thu, 07:25 September 1, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Fri, 23:59 August 26, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Fri, 23:55 August 19, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Thu, 23:55 August 18, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Tue, 06:55 August 16, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: ACSW |


Sat, 01:53 August 13, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Fri, 00:08 August 12, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Thu, 17:52 May 26, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Mon, 23:20 May 16, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Wed, 15:43 May 4, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Tue, 19:10 April 26, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: OTCQB | Source: OTCM |


Sat, 12:56 April 2, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: Pink Current | Source: GLOBE |


Sat, 23:56 March 19, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: Pink Current | Source: GLOBE |


Tue, 08:01 March 15, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: Pink Current | Source: GLOBE |


Sun, 00:26 March 13, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Core One Labs Inc. | Tier: Pink Current | Source: GLOBE |


... further results

More News: Company News | OTC Markets

CLABF Stock

Edit Links page


Create FAQs page


No opinions so far.

Please login or register to post your opinion.